METABOLIC / SINGLE
RETATRUTIDE
5MG · 10MG · 15MG · 20MG · 30MG · 40MG · 50MG · 60MG · 30MGThis content is intended for educational and research reference only and does not constitute medical advice, diagnosis, or treatment. Experimental compounds are for research use only and are not for human consumption. Always consult qualified healthcare providers before starting any therapy.
Research Overview
A triple GLP-1/GIP/glucagon receptor agonist studied in metabolic and weight-management research.
Available Strengths
- 5MG (RT5)
- 10MG (RT10)
- 15MG (RT15)
- 20MG (RT20)
- 30MG (RT30)
- 40MG (RT40)
- 50MG (RT50)
- 60MG (RT60)
- 30MG (RTPEN)
Research Protocol
Reference gradual schedule
| Period | Dose | U-100 units | Volume |
|---|---|---|---|
| Weeks 1–4 | 2 mg | 20 | 0.2 mL |
| Weeks 5–8 | 4 mg | 40 | 0.4 mL |
| Weeks 9–12 | 6 mg | 60 | 0.6 mL |
| Weeks 13+ | 8 mg | 80 | 0.8 mL |
Reconstitution
≈10.0 mg/mL once reconstituted
- Draw 1.0 mL of bacteriostatic water per 10 mg vial.
- Inject slowly along the vial wall to avoid foaming; swirl gently until dissolved.
Research context
Combined receptor agonism is studied for appetite suppression and increased energy expenditure; an approximately six-day half-life supports once-weekly dosing in the reference protocol.
Storage
−20°C or colder, cited as stable up to 24 months. 2–8°C, protected from light, use within 4 weeks.
Research Notes
- For educational and research reference only. Not medical advice and not intended for unsupervised human use.
- Retatrutide remains investigational and is not an approved medicine.
References
Source reference: PeptideDosages.com · 2026-08-18 · Exact strength match with the cited source